Taiwanese biotech built on ‘foundation of lies’, says DoJ
US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.
Roche unit accused of stepping on D&I pledge with lawsuit
Roche unit Spark Therapeutics is pursuing a “misguided” lawsuit that contravenes its stated mission to combat systemic racism, according to gene therapy developer Bluebird Bio.
Poland’s Polpharma asks US court to grant Swiss arbitration in TS case
Poland’s largest pharmaceutical company has asked the federal court to let it pursue arbitration in a Swiss court for a trade secrets dispute between India’s Rubicon Research and North Carolina biotech firm Kartha Pharmaceuticals.
Masimo wants ITC to block Apple watches
Masimo wants to bar Apple from selling the Apple Watch Series 6, alleging the mobile manufacturer infringed five of its blood pressure monitoring patents.
Teva sues two Indian generics over Huntington’s treatment
Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Five minutes with… Dmitry Karshtedt
Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.
UK Supreme Court shoots down NHS £220m drug patent suit
The UK Government has failed to convince UK Supreme Court judges that Servier Laboratories misrepresented its blood pressure drugs patent in legal proceedings to block generic competitors from entering the market.
Minerva: less risk for inventors, more work for the courts
The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Teva and Eagle try to block Bendeka generic
Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
